About Lyell Immunopharma (LYEL)

Lyell Immunopharma, Inc. (LYEL) is a biotechnology company focused on developing novel cell therapies for the treatment of cancer. The company's mission is to create transformative cell therapies that can provide durable and curative responses for patients with solid tumors. LYEL is leveraging its proprietary ex vivo T cell programming platform to engineer T cells with enhanced functionality and persistence. By targeting tumor-specific antigens, these engineered T cells have the potential to recognize and eliminate cancer cells. With an experienced team of scientists and clinicians, LYEL is advancing a pipeline of innovative cell therapies that have the potential to revolutionize cancer treatment.

In terms of stock price history, LYEL is a relatively new company, having gone public in 2021. As such, there is limited historical data available for analysis. However, since its initial public offering (IPO), LYEL has experienced significant volatility in its stock price. Investors should be aware of the potential for price fluctuations in the short term.